For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Xenon Pharmaceuticals Inc (NASDAQ: XENE) closed at $36.52 in the last session, down -0.19% from day before closing price of $36.59. In other words, the price has decreased by -$0.19 from its previous closing price. On the day, 0.7 million shares were traded. XENE stock price reached its highest trading level at $36.83 during the session, while it also had its lowest trading level at $35.97.
Ratios:
We take a closer look at XENE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 15.14 and its Current Ratio is at 15.14. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On May 07, 2025, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $55.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $67.Deutsche Bank initiated its Buy rating on February 11, 2025, with a $67 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 19 ’25 when SHERRY AULIN bought 2,548 shares for $37.08 per share.
GANNON STEVEN sold 3 shares of XENE for $91 on Jun 05 ’25. The Director now owns 7,141 shares after completing the transaction at $30.48 per share. On Jan 24 ’25, another insider, MORTIMER IAN, who serves as the PRESIDENT & CEO of the company, sold 22,468 shares for $40.20 each. As a result, the insider received 903,214 and left with 31,302 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XENE now has a Market Capitalization of 2815903744 and an Enterprise Value of 2337073664. For the stock, the TTM Price-to-Sale (P/S) ratio is 375.45 while its Price-to-Book (P/B) ratio in mrq is 4.43. Its current Enterprise Value per Revenue stands at 311.61 whereas that against EBITDA is -7.408.
Stock Price History:
The Beta on a monthly basis for XENE is 1.13, which has changed by -0.055109978 over the last 52 weeks, in comparison to a change of 0.15101504 over the same period for the S&P500. Over the past 52 weeks, XENE has reached a high of $46.00, while it has fallen to a 52-week low of $26.74. The 50-Day Moving Average of the stock is 2.50%, while the 200-Day Moving Average is calculated to be 2.60%.
Shares Statistics:
According to the various share statistics, XENE traded on average about 1.06M shares per day over the past 3-months and 706590 shares per day over the past 10 days. A total of 76.94M shares are outstanding, with a floating share count of 74.01M. Insiders hold about 4.01% of the company’s shares, while institutions hold 104.39% stake in the company. Shares short for XENE as of 1757894400 were 7040555 with a Short Ratio of 6.67, compared to 1755216000 on 6892652. Therefore, it implies a Short% of Shares Outstanding of 7040555 and a Short% of Float of 10.18.
